S_mnary We attempted to determine whether calcium channel blockers (CCBs) enhance the anti-tumour activity of cis-diamminedichloroplatinum (cisplatin) against both cisplatin-sensitive human glioblastoma U87-MG cells and cisplatin-resistant U87-MG-CR cells, the latter of which we developed for resistance to cisplatin. Nifedipine, a dihydropyridine class CCB, significantly enhanced the anti-tumour effect of cisplatin on these two cell types in vitro and in vivo. Our findings also indicated that, in the absence of normal extracellular Ca2', nifedipine was capable of enhancing the cytotoxicity of cisplatin. In addition, this anti-tumour activity was partially inhibited by actinomycin D and cycloheximide, suggesting that it is possibly dependent upon new RNA and protein synthesis. Interestingly. ultrastructural analysis, DNA fragmentation assay and cell cycle analysis demonstrated that synergism between cisplatin and nifedipine results in apoptosis (programmed cell death) at a relatively low concentration of cisplatin, which when tested alone did not induce apoptosis. Furthermore, we demonstrated that nuclei from these cells lack a Ca-+-dependent endonuclease that degrades chromatin in the linker region between nucleosomes. In conclusion, our studies suggest that the non-cytotoxic agent nifedipine is able to synergistically enhance the anti-tumour effects of cisplatin on U87-MG and U87-MG-CR cells lacking a Ca2'-dependent endonuclease and subsequently to induce apoptosis via interaction of nifedipine with an as yet uncharactenrsed functional site other than a calcium channel on target cells.
Malignant gliomas are among the most difficult human tumours to treat successfully. Despite recent attempts to improve chemotherapeutic approaches to their treatment, success in the treatment of these tumours remains limited. cis-diamminedichloroplatinum (cisplatin) is one of the more effective and more commonly used drugs in the treatment of malignant gliomas (Sexauer et al., 1985; Bertolone et al., 1989) . However, the effectiveness of cisplatin against recurrent tumours is substantially lower than against primary tumours (Randolph et al., 1978; Amer et al., 1979) , probably because of the presence of a population of resistant cells (Bakka et al., 1981) . Recently, Gately and Howell (1993) have reviewed several biochemical alterations that have been reported to be capable of producing cisplatin resistance: (1) decreased cellular accumulation of cisplatin; (2) overexpression of cell-surface glycoprotein analogous to P-glycoprotein and inversely related to the accumulation of cisplatin; (3) increased levels of glutathione (GSH) or of glutathione-Stransferase activity; (4) increased levels of intracellular metallothioneins (MTs); and (5) enhanced DNA repair (Kelly and Rozencweig, 1989; Andrews and Howell, 1990; Kawai et al., 1990; Perez et al., 1990; Timmer-Bosscha et al., 1992) . However, the mechanism of resistance to the cytotoxic effect of cisplatin is not yet clear.
Many investigators have already reported that calcium channel blockers (CCBs) are able to enhance the cytotoxic effect of anti-cancer agents in treatment of drug-resistant tumours (Tsuruo et al., 1982; 1983; Tsuruo, 1983; Helson, 1984; Kessel and Wilberding, 1985) . Recently, Ikeda et al. (1987) have reported that verapamil enhances the antitumour effect of cisplatin on human neuroblastoma cells. Onoda et al. (1986 Onoda et al. ( , 1988 Onoda et al. ( , 1989 have also reported that nifedipine enhances the cytotoxic anti-tumour effects of cisplatin on cisplatin-sensitive and cisplatin-resistant murine melanoma cells and their pulmonary metastases. We have therefore attempted to determine whether CCBs enhance the cytotoxicity of cisplatin for cisplatin-sensitive and cisplatinCorrespondence: S : Eastman. 1990 ) and in a human pre-B-cell leukaemia line 697 (Miyashita and Reed, 1993) . We therefore attempted to determine, using ultrastructural analysis, DNA fragmentation assay and cell cycle analysis, whether the combination chemotherapy with cisplatin and CCB induces apoptosis in glioblastoma cells. We also attempted to determine whether cell death induced by this synergism is due to the activation of endogenous Ca'2-dependent endonuclease.
Materias and methods
Tumour cells U87-MG glioblastoma cell lines were obtained from Riken Cell Bank (Wako, Japan). The cisplatin-resistant U87-MG (U87-MG-CR) cells were developed by a modification of the protocol of Schmid et al. (1980) . First, U87-MG tumour was transplanted subcutaneously into Balb c (nu/nu) female athymic nude mice on day 1. Sequential treatment of subcutaneous tumours with two courses of intraperitoneal cisplatin (2 mg kg-1) on days 14 and 21 was then undertaken. On day 28, tumours were excised and adapted for growth in culture as previously described by Onoda et al. (1986) . The resulting cultures were treated with incrementally increasing (0.3-1.2 ;m) exposures to cisplatin. Typically, exponentially growing cells were treated for 1 day with cisplatin; this was followed by removal of cisplatin, and then readdition at the next highest dose. The cells which survived the in vitro cisplatin treatment were retransplanted into nude mice subcutaneously. Mice bearing the resulting tumours were also treated with the same two courses of cisplatin. On day 28, tumours were excised and used to form cultures in vitro as described above. Cells were then also treated with incremen- (Kondo et al., 1994a) . Briefly, 2 x 10' tumour cells were harvested, washed in PBS, pelleted, prefixed in 2.0% glutaraldehyde for 2 h and washed in 0.1 M phosphate buffer (pH 7.4), followed by post-fixation with 1.0% osmium tetroxide for 2 h. Samples were embedded in Econ 812, sectioned and stained for 20 min in 2.0% aqueous uranyl acetate and for 2 min in lead citrate. Grids were viewed using a JEM-1200EX ekctron microscope (NEC, Tokyo, Japan). Furthermore, DNA fragmentation assay was performed using methods described previously (Kondo et al., 1994b) . Briefly, harvested cells (1 x 10') were centrifuged and washed twice with cold PBS. The cell pellet was lysed in l.Oml of a buffer consisting of 10mm Tris-HCI, 10mM EDTA and 0.2% Triton X-100 (pH 7.5). After 10 min on ice, the lysate was centrifuged (13 000g Isolation of nuclei and determination ofendogenous nuclease activity This assay was performed using methods described previously (Rodriguez-Tarduchy et al., 1992) . Briefly, 5 x 10' tumour cells were pelleted and the nuclei were prepared by resuspension in 10 mM Tris-HCI, 1.5 mM magnesum chloride, pH 7.2, and incubation on ice for 60 min. After washing in 1.5 mm magnesium chloride, nuclei were resuspended in 10mm Tris-HCl, 200mM sucrose and 140mM sodium chloride, pH 7.2. Endogenous nuclease activity was determined after incubation of the suspension of nuclei for 4 h at 37C in the absence or presence of 5 mM calcium chloride and 10mM magnesium chloride. As a control for degradation of chromatin in oligonucleosome-length fragments, micrococcal nuclease (10 U ml', Sigma Figure 9 shows that, in nuclei prepared from tumour ceLls, the addition of calcium did not induce cleavage of DNA into oligonucleosome-length fragments under our assay conditions. A positive control experiment with murine splenocytes prepared as previously described (Rodriguez-Tarduchy et al., 1992) also suggested that the synergism between cisplatin and nifedipine may be the result of nifedipine's ability to alter intracellular levels of calcium via a mechanism independent of the voltage-sensitive calcium channel. For example, CCBs are known to inhibit Ca24 influx into platelets, even though platelets lack the voltage-sensitive calcium channel (Motulsky et al., 1983; Onoda et al., 1984) . Therefore, to determine whether nifedipine synergistically enhances the cytotoxicity of cisplatin against U87-MG and U87-MG-CR cells owing to its effect on Ca2" influx or to an effect at some other functional site, tumour cells cultured in Ca24-free DMEM were assayed for cell viability. Our findings indicate that, in the absence of normal extracellular Ca2", nifedipine was also capable of enhancing the cytotoxicity of cisplatin for tumour cells. This synergism may be activated by nifedipine's effect on a functional site other than the calcium channel. However, there still remains a possibility that nifedipine may be affecting Ca2" signalling from internal stores of Ca2" released from the endoplsmic reticulum. Recently, cisplatin has been shown to induce apoptosis in Chinese hamster ovary cell lines Eastman, 1990) and in a human leukaemia cell line (Miyashita and Reed, 1993) . Interestingly, in this study ultrastructural analysis, DNA fragmentation assay and cell cycle analysis have demonstrated clearly that synergism between cisplatin and nifedipine results in apoptosis at a relatively low concentration of cisplatin which when tested alone does not induce apoptosis. Ormerod et al. (1994) suggest that, at relatively lower doses of isplatin, tumour cells become blocked in G2/M phase, and that there is a major deision point at this stage of the cell cycle. The cells treated with cisplatin either eventually divide or die after stay in G2/M (Sorenson et al., 1990 ). Evans and Dive (1993) also suggest that initiation of cisplatin-induced apoptosis needs to be coupled to a cell cycle-mediated event. Our results show that the combination with cisplatin and nifedipine induced a reduction in G2/M phase cells when compared with cisplatin alone, and accumulated AO peak. This peak has been shown to indicate the presence of apoptotic cells (Telford et al., 1991; Walker et al., 1991; del Bino et al., 1992; Ormerod et al., 1994 In general, apoptosis is characterised by cell shrinkage accompanied by DNA fragmentation owing to the activation of an uncharacterised Ca2+/Mg2+ endonuclease which cleaves the cell's DNA into nucleosome-sized units (Duke et al., 1983; Cohen et al., 1984; Wylie, 1987) . However, our findings suggest that U87-MG and U87-MG-CR cells lack Ca2'-dependent endonuclease, although we cannot rule out the possibility that this assay is limited in its sensitivity and, moreover, such an endonuclease is present in these cells but is destroyed during the preparation of nuclei. An incon- (1990, 1992) have recently reported that calcium ionophores inhibit apoptosis in the interleukin 3 (IL-3)-dependent bone marrow-derived cell line BAF3. by maintaining the cells in a viable non-cycling state. They also suggest that whether apoptosis is induced or inhibited by calcium ionophore depends on whether a calcium-dependent nuclease is present in target cells. Their findings may possibly support our own. In addition, the role of the endonuclease per se. which cleaves to 180 bp fragments, has been called into question recently. It appears that this type of fragmentation is a late and even dispensable event in the apoptotic process, and that it can be inhibited without preventing the morphological changes in the nucleus (Oberhammer et al., 1993) . The combination with cisplatin and nifedipine may affect the late process of apoptosis. On the other hand, Johnson and Byerly (1991, 1993) have recently demonstrated that all the Ca' channels can be blocked by the increase in intracellular Ca>+ in neuronal cells. Therefore, the role of calcium as a signal for apoptosis remains controversial.
In conclusion, we hypothesise that nifedipine synergistically enhances the anti-tumour effect of cisplatin on both cisplatin-sensitive and cisplatin-resistant human glioblastoma cells and induces apoptosis in these tumour cells, via interaction of nifedipine with an as yet uncharacterised functional site other than a calcium channel on target cells. Until recently, in clinical investigations various chemosensitisers. including verapamil, were used as a modulation of resistance (Ozolos et al., 1987) . The main problem with this chemosensitisation is the inability to attain plasma levels in patient, corresponding with in vitro effective concentrations. because of the observed cardiovascular toxicity (Ozolos et al., 1987) . However, our study described here suggests that, if an uncharacterised functional site with which nifedipine interacts is clarified, the novel chemosensitiser without major toxicities may be applicable in the treatment of primary and recurrent malignant gliomas because it has no use of calcium antagonistic activity. In addition, further studies are necessary to determine the mechanism of resistance in U87-MG-CR cells and, moreover, whether nifedipine alters the accumulation of cisplatin, the levels of GSH, the levels of MTs and DNA repair in tumour cells.
